Evidence map›Paper›PMID 32852697›Full record

ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2020

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?

David M Williams, Marc Evans

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. PhenoFit: a framework for determining computable phenotyping algorithm fitness for purpose and reuse.Journal of the American Medical Informatics Association : JAMIA · 2026
    Article
  5. Review
  6. Effect of low-level laser physiotherapy on left ventricular function among patients with chronic systolic heart failure.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes.European heart journal supplements : journal of the European Society of Cardiology · 2021
    Article
  13. Management of Obesity in Cardiovascular Practice: JACC Focus Seminar.Journal of the American College of Cardiology · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David M WilliamsDepartment of Diabetes and Endocrinology, University Hospital Llandough, Cardiff, UK. david.williams@doctors.org.uk.ORCID http://orcid.org/0000-0001-9206-5837
Marc EvansDepartment of Diabetes and Endocrinology, University Hospital Llandough, Cardiff, UK.
University Hospital Llandough · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are often limited to diuretics to improve symptoms as no therapies demonstrate a mortality benefit in this cohort. People with diabetes have a high risk of developing HFpEF and vice versa, suggesting shared pathophysiological mechanisms exist, which in turn engenders the potential for shared treatments. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor which has demonstrated significantly improved cardiovascular and hospitalisation for heart failure (HHF) outcomes in previous cardiovascular outcome trials (CVOTs). These CVOTs include the DECLARE-TIMI and DAPA-HF studies which observed significant benefits for people with heart failure and specifically those with heart failure and reduced ejection fraction (HFrEF), respectively. The ongoing DELIVER study is evaluating the use of dapagliflozin specifically in people with HFpEF, which may have enormous implications for treatment and considerable economic consequences. This will complement previous and other ongoing CVOTs evaluating dapagliflozin use. In this review we discuss the use of SGLT2 inhibitors in HFrEF and HFpEF with a focus on the DELIVER study and its potential health and economic implications.

Indexed as

DapagliflozinDELIVER studyHeart failurePreserved ejection fractionSGLT2 inhibitorsType 2 diabetes

Identifiers

PMID32852697
PMCPMC7509021
OpenAlexW3080082414

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.